Southern African guidelines on the safe, easy and effective use of pre-exposure prophylaxis: 2020

Linda-Gail Bekker¹, Benjamin Brown², Dvora Joseph-Davey^{3

4}, Kathrine Gill¹, Michelle Moorhouse⁵, Sinead Delany-Moretlwe⁵, Landon Myer⁴, Catherine Orrell^{1

6}, Kevin Rebe^{7

8}, W D Francois Venter⁹, Carole L Wallis¹⁰

Affiliations

¹ Desmond Tutu HIV Centre, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.
² Anova Health Institute, Johannesburg, South Africa.
³ Department of Epidemiology, University of California, Los Angeles, United States of America.
⁴ Division of Epidemiology and Biostatistics, School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa.
⁵ Wits Reproductive Health and HIV Research Unit, University of the Witwatersrand, Johannesburg, South Africa.
⁶ Department of Medicine, University of Cape Town, Cape Town, South Africa.
⁷ Life Vincent Pallotti Hospital, Cape Town, South Africa.
⁸ Department of Medicine and Infectious Diseases, University of Cape Town, Cape Town, South Africa.
⁹ Ezintsha, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
¹⁰ BARC-SA, Speciality Molecular Division, Lancet Laboratories, Johannesburg, South Africa.

Linda-Gail Bekker et al. South Afr J HIV Med. 2020.

. 2020 Dec 10;21(1):1152.

doi: 10.4102/sajhivmed.v21i1.1152. eCollection 2020.

¹ Desmond Tutu HIV Centre, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.
² Anova Health Institute, Johannesburg, South Africa.
³ Department of Epidemiology, University of California, Los Angeles, United States of America.
⁴ Division of Epidemiology and Biostatistics, School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa.
⁵ Wits Reproductive Health and HIV Research Unit, University of the Witwatersrand, Johannesburg, South Africa.
⁶ Department of Medicine, University of Cape Town, Cape Town, South Africa.
⁷ Life Vincent Pallotti Hospital, Cape Town, South Africa.
⁸ Department of Medicine and Infectious Diseases, University of Cape Town, Cape Town, South Africa.
⁹ Ezintsha, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
¹⁰ BARC-SA, Speciality Molecular Division, Lancet Laboratories, Johannesburg, South Africa.

Erratum in

Corrigendum: Southern African guidelines on the safe, easy and effective use of pre-exposure prophylaxis: 2020.
Bekker LG, Brown B, Joseph-Davey D, Gill K, Moorhouse M, Delany-Moretlwe S, Myer L, Orrell C, Rebe K, Francois Venter WD, Wallis CL. Bekker LG, et al. South Afr J HIV Med. 2021 Dec 8;10:1295. doi: 10.4102/sajhivmed.v22i1.1295. eCollection 2021. South Afr J HIV Med. 2021. PMID: 34956660 Free PMC article.

No abstract available

The authors have declared that no competing interest exists.

1. Bekker LG, Rebe K, Venter F, et al. . Southern African guidelines on the safe use of pre-exposure prophylaxis in persons at risk of acquiring HIV-1 infection. S Afr J HIV Med. 2016;17(1):455 10.4102/sajhivmed.v17i1.455 - DOI - PMC - PubMed
1. Baeten JM, Donnell D, Ndase P, et al. . Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367(5):399–410. 10.1056/NEJMoa1108524 - DOI - PMC - PubMed
1. Grant RM, Lama JR, Anderson PL, et al. . Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587–2599. 10.1056/NEJMoa1011205 - DOI - PMC - PubMed
1. Peterson L, Taylor D, Roddy R, et al. . Tenofovir disoproxil fumarate for prevention of HIV infection in women: A phase 2, double-blind, randomized, placebo-controlled trial. PLoS Clin Trials. 2007;2(5):e27 10.1371/journal.pctr.0020027 - DOI - PMC - PubMed
1. Thigpen MC, Kebaabetswe PM, Paxton LA, et al. . Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012;367(5):423–434. 10.1056/NEJMoa1110711 - DOI - PubMed